Our Company
John Lagus is passionate about helping patients around the world with unmet medical needs get access to medicines for serious or life-threatening diseases by supporting pharma and biotech companies implement the most effective global early access program for their unique situation.
Over the past 18 years he has been involved with the design, set up, and implementation of more than 200 global early access programs including expanded access programs in the US. John works with companies to leverage his subject matter expertise to implement best practices for all stakeholders.
John began his career in pharma in 1991 as a statistician at 3M Pharmaceuticals and then joined Orphan Medical in 1994 to oversee the development and FDA approval of ANTIZOL. He held development, commercial, business development, and international roles while at Orphan Medical.
In 2006 John joined Idis, the pioneer in developing the concept of named patient programs. During his 12 years at Idis (and later Clinigen), John held various operational, commercial and management roles. He joined Tanner Pharma Group in 2019 and spent 4 years educating biotech and pharma companies about the early access space, and then designing and supporting implementation of their global early access programs.
With compassion as our compass, BLUESTEM PHARMA CONSULTING was founded to support pharma and biotech companies unlock the power and benefits of early access programs.
JOHN LAGUS
Founder of BLUESTEM PHARMA CONSULTING
John Lagus is passionate about helping patients around the world with unmet medical needs get access to medicines for serious or life-threatening diseases by supporting pharma and biotech companies implement the most effective global early access program for their unique situation.
Over the past 18 years he has been involved with the design, set up, and implementation of more than 200 global early access programs including expanded access programs in the US. John works with companies to leverage his subject matter expertise to implement best practices for all stakeholders.
John began his career in pharma in 1991 as a statistician at 3M Pharmaceuticals and then joined Orphan Medical in 1994 to oversee the development and FDA approval of ANTIZOL. He held development, commercial, business development, and international roles while at Orphan Medical.
In 2006 John joined Idis, the pioneer in developing the concept of named patient programs. During his 12 years at Idis (and later Clinigen), John held various operational, commercial and management roles. He joined Tanner Pharma Group in 2019 and spent 4 years educating biotech and pharma companies about the early access space, and then designing and supporting implementation of their global early access programs.
